Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Therapeutic apheresis

• Publication date

  2001-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1526-0968.2001.00350.XPMID 11724509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma fibrinogen and factor VII as risk factors for cardiovascular disease

  2004cited by this paper
• Overview of hemostasis

  2002cited by this paper
• Intraindividual Comparison of the Impact of two Selective Apheresis Methods (DALI and HELP) on the Coagulation System

  2000cited by this paper
• Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies.

  2000cited by this paper
• Heparin-mediated extracorporeal LDL/fibrinogen precipitation--H.E.L.P.--in coronary and cerebral ischemia.

  1999cited by this paper
• Increased cerebral CO(2) reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia.

  1999cited by this paper
• Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients.

  1999cited by this paper
• Improvement of coronary vasodilatation capacity through single LDL apheresis.

  1998cited by this paper
• Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.

  1998cited by this paper
• Safety and effectiveness of long-term LDL-apheresis in patients at high risk.

  1998cited by this paper
• Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.

  1998cited by this paper
• Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics.

  1997cited by this paper
• Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.

  1997cited by this paper
• Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis.

  1997cited by this paper
• Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation.

  1997cited by this paper
• Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation.

  1996cited by this paper
• Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1995cited by this paper
• Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.

  1994cited by this paper
• Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Plasma fibrinogen and its correlates in Japanese and US population samples.

  1993cited by this paper
• Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.

  1993cited by this paper
• Improved Neurological Recovery of Cerebral Infarctions After Plasmapheretic Reduction of Lipids and Fibrinogen

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Plasma fibrinogen and factor VII as risk factors for cardiovascular disease.

  1992cited by this paper
• The possible role of hemorheology in atherothrombogenesis.

  1992cited by this paper
• Hemostasis and cardiovascular risk. The British and European experience.

  1992cited by this paper
• The HELP‐LDL‐apheresis multicentre study, an angiographically assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease

  1991cited by this paper
• Haemostatic changes after heart transplantation and their relationship to accelerated coronary sclerosis.

  1991cited by this paper
• Plasma fibrinogen — an independent cardiovascular risk factor

  1990cited by this paper
• The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life.

  1990cited by this paper
• Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin‐induced extracorporeal LDL precipitation (HELP) *

  1989cited by this paper
• Hypercoagulability and ischaemic heart disease.

  1987cited by this paper
• The effect of physiological levels of fibrinogen on platelet aggregation.

  1985cited by this paper
• Internal duplication and sequence homology in factors V and VIII.

  1985cited by this paper
• Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens

  1957cited by this paper
• [Rapid physiological coagulation method in determination of fibrinogen].

  1957cited by this paper

• Long Covid Patients Successfully Treated by Means of Heparin-Mediated Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis

  2023cites this paper
• The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19

  2022influential citation
• How to improve clotting factors depletion in double‐filtration plasmapheresis

  2021cites this paper
• Valproic acid influences the expression of genes implicated with hyperglycaemia-induced complement and coagulation pathways

  2021cites this paper
• Valproic acid attenuates hyperglycemia-induced complement and coagulation cascade gene expression

  2018cites this paper
• Lipoprotein apheresis reduces circulating galectin‐3 in humans

  2016cites this paper
• Lipoprotein Apheresis

  2015cites this paper
• Lipoproteinapherese – Wie sieht die Praxis aus?

  2013cites this paper
• Biomarkers of heart transplant rejection: the good, the bad, and the ugly!

  2012cites this paper
• Early Prediction of Cardiac Allograft Vasculopathy and Heart Transplant Failure

  2011cites this paper
• Hematologic and hemostatic changes induced by different columns during LDL apheresis

  2010cites this paper
• Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial

  2009cites this paper
• Pleiotropic effects of LDL apheresis.

  2009cites this paper
• Protein adsorption during LDL-apheresis: proteomic analysis.

  2008cites this paper
• What's going on in LDL apheresis.

  2007cites this paper
• Effects of HELP Therapy on Acute Ischemic Stroke and Vascular Endothelial Cell Function

  2007cites this paper
• Fibrinogen Apheresis in the Treatment of Peripheral Arterial Disease

  2007cites this paper
• Dopplersonographische Messung der zerebralen Reservekapazität bei Patienten mit HELP Lipid Plasmapherese

  2006cites this paper
• Is the Efficacy of LDL Apheresis in Ischemic Optic Neuropathy Linked to a Reduction in Endothelial Activation Markers?

  2006cites this paper
• [Atherogenesis: interplay between cholesterol, inflammation and coagulation].

  2005cites this paper
• Heparin-mediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion.

  2005cites this paper
• EXTRACORPOREAL PLASMA TREATMENT FOR THE REMOVAL OF ENDOTOXIN IN PATIENTS WITH SEPSIS: CLINICAL RESULTS OF A PILOT STUDY

  2005cites this paper
• Atherogenese: Wechselspiel zwischen Cholesterin, Inflammation und Koagulation

  2005cites this paper
• Endothelial Cell Biology: Inflammatory Biomarkers and Risk of Transplant Atherosclerosis

  2004cites this paper
• Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins--reduction of circulating proinflammatory and procoagulatory markers.

  2004cites this paper
• Dialysis techniques: therapeutic plasma exchange and related techniques

  2004cites this paper
• Lipidfiltration--safe and effective methodology to perform lipid-apheresis.

  2004influential citation
• The HELP System for the Treatment of Atherothrombotic Disorders: A Review

  2003cites this paper
• From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis

  2003cites this paper
• Stellenwert der LDL-Apherese in der Behandlung der koronaren Herzerkrankung

  2003influential citation
• Fibrinogen und Atherothrombose: vulnerable Plaque oder vulnerabler Patient?

  2003cites this paper
• [Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?].

  2003cites this paper
• Simultaneous Determination of Low Free Mg2+ and pH in Human Sickle Cells using 31P NMR Spectroscopy* 210

  2002cites this paper
• Case reports on emergency treatment of cardiovascular syndromes through heparin-mediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage.

  2002cites this paper
• Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis.

  2001cites this paper